Clinical Trial Update: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating QL1706 in combination with chemotherapy as neoadjuvant therapy for triple-negative breast cancer and is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• QL1706

Snippet

Sponsor: Affiliated Hospital of Nantong University | Conditions: Triple Negative Breast Cancer (TNBC) | Phase 2 | Status: RECRUITING